Tokyo Women's Medical University Journal
Online ISSN : 2432-6186

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

Secondary Publication: Role of Molecular Targeted Drugs in Oncology
Hidekazu Kuramochi
著者情報
ジャーナル オープンアクセス 早期公開

論文ID: 2023004

この記事には本公開記事があります。
詳細
抄録

Recent advances in molecular biology have led to the identification of molecules associated with carcinogenesis and the development of molecular-targeted drugs that selectively attack qualitative or quantitative molecular changes in cancer cells. Molecular targeted drugs are classified into "low molecular weight compounds" and "monoclonal antibody drugs" according to the difference in molecular weight. Molecular targeted drugs often have clinically meaningful biomarkers, such as gain- or loss-of-function in cancer-related target genes caused by point mutations, amplification, fusion, and deletion. High therapeutic effects can be expected by detecting driver mutations, which are directly related to carcinogenesis, and by using the corresponding molecular-targeted drugs. In recent years, the development of next-generation sequencing has enabled the simultaneous measurement of hundreds of gene sequences, and an oncogene panel containing cancer-related genes has been covered by the National Health Insurance. Precision medicine is defined as medical care designed to optimize the efficiency or therapeutic benefit for specific patient groups, especially using genetic or molecular profiling.

This article is based on a study reported in the Journal of Tokyo Women's Medical University (in Japanese) 2022;92 (1):1-7.

著者関連情報
© 2023 Society of Tokyo Women's Medical University

This is an open access article distributed under the terms of Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original source is properly credited.
https://creativecommons.org/licenses/by/4.0/deed.ja
feedback
Top